Company Overview
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company based in the United States, focusing its efforts on developing proprietary therapeutic candidates for various medical indications. The company's primary asset is the FB-102, a proprietary anti-CD122 monoclonal antibody designed to treat autoimmune and autoimmune-related conditions, including graft-vs-host disease. This entity functions within the broader Healthcare sector and specifically within the Biotechnology industry, a domain characterized by high research and development costs and regulatory complexity before products reach commercialization. The company's current market capitalization stands at $330.46M, supported by a workforce of 16 employees and annual revenue figures that are not publicly disclosed in the current reporting period. This valuation of $330.46M relative to its small employee base and lack of reported revenue suggests the company is in a pre-commercialization phase where market value is derived primarily from the potential of its pipeline assets rather than current operational cash flows or sales volume.
Financial Health
The company reports a Net Income (TTM) of $-51,742,000 and an EBITDA of $-53,382,000, while Revenue (TTM) is listed as N/A, indicating that the firm has not yet generated significant commercial sales to cover its substantial operating expenses. The significant gap between revenue and net income, compounded by the absence of reported revenue, reveals a cost structure dominated by research, development, and administrative overheads typical of early-stage biotechnology ventures. Free Cash Flow stands at $-24,480,124, which indicates that the company is currently burning cash to fund its operations and clinical trials, limiting its immediate financial flexibility without external capital injections. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, reflecting that the company has not yet crossed the threshold into profitable operations where these metrics would become meaningful indicators of efficiency. The balance sheet shows a Cash position of $93.41M against a Debt level of N/A, and since the Debt to Equity ratio is N/A, the absence of reported debt suggests the company is currently un-levered, relying on its cash reserves to sustain operations. The Current Ratio is 7.34, a figure that indicates strong short-term liquidity, suggesting the company holds sufficient current assets to cover its short-term liabilities many times over. Finally, the Return on Equity is -110.7% and the Return on Assets is -58.1%, metrics that reveal management is currently deploying capital at a loss, a common characteristic of clinical-stage companies yet one that signals a need for successful product milestones to reverse these negative return profiles.
Valuation Assessment
The Trailing P/E Ratio (TTM) is N/A due to the lack of positive earnings, while the Forward P/E is reported as -7.36, a negative figure that implies analysts do not expect immediate profitability and that the earnings trajectory is currently negative. The Price to Book ratio is 5.59, a metric that indicates the market is pricing the company at a significant premium over its net asset value, likely reflecting the high potential value assigned to its intellectual property and pipeline assets. The Price to Sales ratio is N/A because revenue data is not available, and the EV/EBITDA stands at -4.44, which serves as an alternative valuation metric suggesting the company is being valued based on a multiple that accounts for its negative earnings and high growth potential. The 52-Week High is $35.62 and the 52-Week Low is $4.90, placing the current trading environment within a wide range that highlights the asset's high volatility and sensitivity to clinical trial results or sector shifts. The Beta is 3.21, a value that signifies the stock's price volatility is more than three times that of the broader market, indicating that investors should expect sharp price swings that amplify both potential gains and losses relative to a standard market index.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet generated sufficient historical revenue data to calculate year-over-year expansion rates or meaningful earnings growth metrics. Since earnings are currently negative and revenue is not reported, any future growth in earnings would be faster than revenue growth only once the company achieves commercial sales, at which point the margin expansion would define the growth dynamic. Regarding income, the Dividend Yield is N/A and the Payout Ratio is 0.0%, which confirms that the company does not distribute dividends to shareholders. This absence of dividend payments is consistent with the company's stage of development, as it reinvests all available earnings and cash reserves into research and development rather than paying out income to investors. The overall growth and income profile is characterized by a lack of current financial returns and dividend distributions, with value entirely contingent on the successful execution of the FB-102 therapeutic candidate and the eventual realization of commercial revenue.